Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1451-1460
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1451
Table 1 Anthropometric, biochemical, and histological features of the overall population included (176 patients)
Classification
Features
Sex, n (%)Female: 142 (80.7)
Age (median)64 yr (IQR: 53–71)
APCA positivity, n (%)147 (83.5)
Gastrin668 pg/mL (IQR: 340–1200)
Chromogranin A (median)146 ng/mL (IQR: 106–219)
ECL hyperplasia, n (%)Absent: 60 (34.1)
Gastric mucosa atrophy, n (%)OLGA
0: 58 (32.9)
I: 38 (21.6)
II: 64 (36.4)
III: 13 (7.4)
IV: 3 (1.7)
Gastric mucosa intestinal metaplasia, n (%)OLGIM
0: 42 (23.9)
I: 63 (35.8)
II: 61 (34.7)
III: 5 (2.8)
IV: 5 (2.8)
BMI: Body mass index; APCA: Anti-parietal cell antibodies; ECL: Enterochromaffin-like cells; OLGA: Operative Link for Gastritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment.
Table 2 Anthropometric, biochemical, and histological differences between patients with diagnosed chronic atrophic autoimmune gastritis who developed gastric neuroendocrine tumors and patients with atrophic autoimmune gastritis who did not develop gastric neuroendocrine tumors, n (%)
AIG patients without gNENs
AIG patients with gNENs
P value
Sex (%)84.3 (female)78 (female)0.06
Age (median)61 yr (IQR: 50–69)66 yr (IQR: 55–73)0.68
Autoimmune tyroiditis48 (42)13 (39)0.46
Type 2 diabetes mellitus 33 (29)11 (33)0.33
Psoriasis and/or vitiligo6 (5)3 (9)0.12
Auntoimmune polyglandular syndrome5 (4)2 (6)0.23
APCA positivity78 (89.7)25 (75.8)1.00
ECL simple/linear hyperplasia29 (33.3)7 (21)1.01
ECL micronodular hyperplasia23 (26.4)11(33.3)0.73
ECL macronodular hyperplasia6 (6.8)1 (3)0.94
OLGIM II–IV34 (39.1)17 (51.5)0.49
Chromogranin A (median)172 ng/mL (IQR: 107–320)160 ng/mL (IQR: 115–217)0.68
Gastrin (median)688 pg/mL (IQR: 423–1200)992 pg/mL (IQR: 449–1500)0.03
AIG: Auto-immune gastritis; APCA: Anti-parietal cell antibody; ECL: Enterochromaffin-like cells; OLGIM: Operative Link on Intestinal Metaplasia Assessment; gNENs: Gastric neuroendocrine neoplasms.